Cargando…
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
High ERβ/HER oncogenic signaling defines lung tumors with an aggressive biology. We previously showed that combining the anti-estrogen fulvestrant with the pan-HER inhibitor dacomitinib reduced ER/HER crosstalk and produced synergistic anti-tumor effects in immunocompromised lung cancer models, incl...
Autores principales: | Almotlak, Abdulaziz A., Farooqui, Mariya, Soloff, Adam C., Siegfried, Jill M., Stabile, Laura P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745184/ https://www.ncbi.nlm.nih.gov/pubmed/35008514 http://dx.doi.org/10.3390/ijms23010081 |
Ejemplares similares
-
Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021) -
Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
por: Preet, Ranjan, et al.
Publicado: (2018) -
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019) -
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer
por: Siegfried, Jill M., et al.
Publicado: (2017) -
Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)